GSK (GSK) announced new preliminary data for AREXVY in adults aged 18-49 at increased risk for lower respiratory tract disease, LRTD, caused by ...

“These promising data add to the evidence supporting GSK’s RSV vaccine and could help expand protection to more adults at ...

Arexvy is currently approved for active immunization for the prevention of LRTD caused by RSV in individuals 60 years of age and older, and those 50 to 59 years of age who are at increased risk for ...

GSK unveils new Arexvy data showing strong protection in adults 18-49 at risk for RSV. The vaccine could broaden coverage for ...

GlaxoSmithKline (GB:GSK) has released an update. GSK has announced promising new data for its RSV vaccine, Arexvy, which ...

After making a splash in the U.K. earlier this year, GSK is laying out plans for its biggest U.S. manufacturing investment ...

GSK (NYSE:GSK) reported its RSV vaccine Arexvy elicited a robust immune response in recipients aged 18 to 49 years who were ...

LSL PHARMA GROUP INC. ("LSL Pharma" or the "Corporation"), an integrated Canadian-based pharmaceutical company, reports that it will make on October 31, 2024, the first interest payment (the "Interest ...

DefenAge Skincare is excited to announce the launch of its newest innovation, the 12-Factor Revitalizing Lip Enhancer. Powered by DefenAge's patented Age-Repair Defensins®, this groundbreaking lip ...

The US pharma giant Pfizer recently announced that its respiratory syncytial virus (RSV) vaccine Abrysvo has received FDA ...

European stocks climbed on Thursday as strong earnings from a slew of companies and dovish comments from Bank of England (BoE) ...

GSK said a single dose of Arexvy elicited a "robust immune response" with an acceptable safety profile in adults aged 18-49 ...